← All trials
NCT01110044
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2010
- Primary completion
- Aug 1, 2012
- Completion date
- Aug 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- GlaxoSmithKlineLead sponsor
- GlaxoSmithKlineStudy director
Drugs studied
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- acellular pertussis vaccine
- 10-valent Pneumococcal Conjugate Vaccine
- 10-valent Pneumococcal Conjugate Vaccine
- human rotavirus, live attenuated
- human rotavirus, live attenuated
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.